NASDAQ:ALT
Altimmune, Inc. Stock News
$8.01
-0.89 (-10.00%)
At Close: May 17, 2024
ALT Stock: Why It Substantially Decreased Today
11:32am, Tuesday, 28'th Sep 2021
The stock price of Altimmune Inc (NASDAQ: ALT) fell by over 19% during intraday trading today. This is why it happened.
Why Altimmune Stock Is Under Pressure Today
11:17am, Tuesday, 28'th Sep 2021
Safety concerns poured water on otherwise positive clinical trial results for the company's experimental weight-loss drug.
See Why Altimmune Stock Plunged After Obesity Trial Data
10:10am, Tuesday, 28'th Sep 2021
Altimmune Inc (NASDAQ: ALT) has announced results from a 12-week, Phase 1 trial of pemvidutide (ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist. At 12 week
Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers
07:01am, Tuesday, 28'th Sep 2021
GAITHERSBURG, Md., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from a 12-week, Phase 1 trial of pemv
Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
04:01pm, Monday, 27'th Sep 2021
GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report the results from its 12-week Phase
Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
04:01pm, Tuesday, 07'th Sep 2021
GAITHERSBURG, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during
Are Options Traders Betting on a Big Move in Altimmune (ALT) Stock?
10:00am, Friday, 27'th Aug 2021
Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.
Altimmune, Inc. (ALT) CEO Vipin Garg on Q2 2021 Results - Earnings Call Transcript
12:29pm, Wednesday, 11'th Aug 2021
Altimmune, Inc. (ALT) CEO Vipin Garg on Q2 2021 Results - Earnings Call Transcript
Altimmune, Inc. (ALT) Reports Q2 Loss, Misses Revenue Estimates
07:19pm, Tuesday, 10'th Aug 2021
Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 9.09% and -93.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
04:01pm, Tuesday, 10'th Aug 2021
12-week Data Readout from ALT-801 Phase 1 Clinical Trial Expected in September
Will Altimmune, Inc. (ALT) Report Negative Q2 Earnings? What You Should Know
04:47pm, Tuesday, 03'rd Aug 2021
Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Heads Into H2 With Stocks on a Streak
03:24pm, Friday, 02'nd Jul 2021
Wall Street crossed over into the second half of the year, as well as a new month and quarter this week, and the transition was a seamless one.
Why Altimmune Is Crashing Today
03:59pm, Wednesday, 30'th Jun 2021
The company halts development on both a COVID-19 vaccine and a drug targeting the disease.
ALT Stock Price Falls Over 35%: Why It Happened
01:57pm, Wednesday, 30'th Jun 2021
The stock price of Altimmune Inc (NASDAQ: ALT) fell by over 35% during intraday trading. This is why it happened.
ALT in Freefall After Covid-19 Vaccine Trials Scrapped
09:54am, Wednesday, 30'th Jun 2021
Altimmune Inc (NASDAQ:ALT) is already taking its place as one of the worst performing stocks on the Nasdaq today, down 30.8% at $11 this morning, following news that the company dropped the developmen
